Cashu FinanceCashu Finance
  • Terminal
  • Pulse
  • Spotlight
  • News
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. OTC
  4. NVSEF

Market Cap: $295.56B

NA

Novartis AG

NVSEF
OTC (Other OTC)USD
Invest in NVSEF
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksScreenersAboutAuthorsAdvertisersBrokersConferencesContact

Legal

Terms of ServicePrivacy PolicyEditorial PolicyCorrections Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

$156.50
-$2.95(-1.85%)
At close: Nov 18, 21:16 EST

More on Novartis AG

  • News & announcements
  • Financials

Novartis AG at a Glance

  • Highly profitable: keeps 18.1% of revenue as net profit.

Open

$149.90

Prev. Close

$159.45

High

$158.24

Low

$149.90

Key Statistics

52-Week Range69% of range
Low $123.69High $171.29
Market Cap
$295.56B
P/E Ratio
30.76x
EPS (TTM)
$5.23
Revenue (TTM)
$54.5B
Dividend Yield
2.76%
Price / Book
8.11x
Beta
0.49
Avg. Volume
25.01K

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

CEOVasant Narasimhan
SectorHealthcare
IndustryDrug Manufacturers - General
Employees75.3K
IPO DateApr 26, 2010
ExchangeOTC
Exchange NameOther OTC
CurrencyUSD
Headquarters & Contact
AddressLichtstrasse 35
City / State / ZIPBasel, BS, 4056
CountrySwitzerland
Phone

NVSEF Stock FAQ

What does Novartis AG do?

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).

Where is Novartis AG stock listed?

Novartis AG trades on the Other OTC under the ticker NVSEF, priced in USD.

What is Novartis AG's market cap?

Novartis AG has a market capitalisation of $295.56B, based on its latest share price.

What is the P/E ratio of NVSEF?

NVSEF trades at 30.76 times its trailing 12-month earnings.

What is NVSEF's 52-week high and low?

Over the past 52 weeks NVSEF has traded between $123.69 and $171.29.

Does Novartis AG pay a dividend?

Yes. Novartis AG's dividend yields 2.76% at the current share price, paying out 90% of its earnings.

Is Novartis AG profitable?

Highly profitable: keeps 18.1% of revenue as net profit.

What do analysts think of NVSEF stock?

The analyst consensus rating for NVSEF is Hold.

Who is the CEO of Novartis AG?

Vasant Narasimhan is the CEO of Novartis AG, which is headquartered in Basel.

Shares trade 3% below a discounted cash flow (DCF) estimate of $161.74.
  • Moderate debt: borrowings are 1.30x shareholders' equity.
  • Strong Piotroski F-Score of 7/9, so fundamentals are improving.
  • Short-term obligations exceed short-term assets (current ratio 0.88).
  • Analyst consensus rating: Hold.
  • Generated automatically from reported financial data. General information only, not financial advice.

    Fundamentals Scorecard

    Each pillar is scored out of 5 from the latest reported data.

    • Valuation

      Weak · 2.3/5

      Price vs earnings, book value and discounted cash flow.

    • Profitability

      Strong · 5.0/5

      Return on equity and return on assets.

    • Financial Health

      Fair · 3.0/5

      Debt levels and Altman Z-Score bankruptcy risk.

    • Fundamental Trend

      Strong · 3.9/5

      Piotroski F-Score: 9 checks on profit, leverage and efficiency.

    See the full financial breakdown →
    41 61 324 1111
    Websitehttps://www.novartis.com